The Reagent Insider: Advancing Alzheimer’s research
Tips, insights and updates
As the leading cause of dementia, Alzheimer’s disease impacts over 50 million people worldwide. In Australia, dementia has recently overtaken heart disease as the leading cause of death, particularly among women. While current treatments focus on symptoms, new research aims to target the underlying disease from clearing amyloid-β, inhibiting tau aggregation, and modulating neuroinflammation to understanding the gut-brain axis and early metabolic changes in AD.
Hot Product
StressMarq’s high-quality tau, amyloid-β, and alpha-synuclein proteins support research into the mechanisms underlying Alzheimer’s disease. Contact us for details.
Exploring the Gut-Brain Link in Alzheimer’s
Emerging studies show gut health influences cognitive function, with a balanced microbiome and Mediterranean diet potentially lowering dementia risk. Using Norgen Biotek’s Stool Nucleic Acid Collection and Preservation Systems, researchers are uncovering novel approaches to tackle cognitive decline.
Connect with Narisa Dawar to learn more about Norgen Biotek.
Lab Favourite
Silence Alzheimer’s-related genes with siRNA.
Targeting tau reveals its role in microtubule stability and neurofibrillary tangles. Check out Revvity’s Dharmacon™ siRNA solutions.
MedChemExpress Neurodegenerative Disease-related Compound Library
This library of 2,960 compounds targets amyloid-β, dopamine receptors, COMT, LRRK2, 5-HT receptors, and more! Perfect for high-throughput, high-content screening of neurodegenerative mechanisms and potential treatments for Alzheimer’s, Parkinson’s, and MND.
Curious about MCE’s compound libraries? Christine Goy is just an email away!
Protocol Tip
Stay on track in Alzheimer’s research. Use InvivoGen’s Mycoplasma Strip to detect contamination early to ensure reliable neuronal and glial culture results. Email Christine Goy for details.
Metabolomics and the Brain
Understanding early metabolic changes in Alzheimer’s disease may identify new therapeutic targets and predictive biomarkers. Metabolomics can detect these subtle biological shifts before clinical symptoms appear, supporting the development of early interventions and treatments that may improve outcomes for people with AD.
